A common component of the contraceptive pill (progesterone) could improve the neurologic outcome for patients with severe head injuries, according to a study published in BioMed Central’s open access journal Critical Care.
Traumatic brain injury (TBI), such as that caused by traffic accidents, falls and sporting injuries, is a major cause of death and disability. A number of ‘neuroprotective’ drugs have been shown to prevent nerve-cell death in animal models of traumatic brain injury, but these findings have not been translated into trials involving people with head injuries.
Progesterone is a female hormone used in the oral contraceptive pill. Preliminary animal and human studies suggest that progesterone could be a useful and safe way to treat acute severe traumatic brain injury, but its neuroprotective effects are unclear. Now, Chinese researchers have shown that progesterone can improve the neurologic outcome of patients with this kind of brain injury for up to six months.
A research team from Hangzhou Normal University and Zhejiang University in Hangzhou, supervised by Professor Weiqi Yan, studied 159 patients with acute traumatic brain injury admitted to a single hospital. In this randomized, double-blinded trial approximately half the patients received progesterone and the other half placebo for five days after brain injury.
“Although previous studies in animal suggest that progesterone may mitigate the severity of brain damage, there is no information about therapeutic benefit of post-TBI progesterone injections in the patients with severe brain trauma” said Professor Yan. “Our work was to determine if progesterone improve chances for recovery in patients with severe injuries in a longer-term”.
Patient outcomes were classified either as favourable (good recovery or moderate disability) or unfavourable (severe disability, vegetative state or death). Neurological outcomes were measured using the Glasgow Outcome Scale, a medical system for evaluating the functional outcome of patients.
At both three and six months after treatment, significantly more patients given progesterone had favourable outcomes compared to patients given placebo. Progesterone was also linked to increased survival at six months. No complications or adverse events were seen in the patients given progesterone.
"We found encouraging evidence that progesterone may significantly improve 6-month neurologic outcome of the patients who were enrolled with acute severe TBI” according to lead author, Dr Giomin Xiao. “Our results provide information important for further multicenter clinical trials on progesterone as a promising neuroprotective drug”.
Source: BioMed Central
Related stories:
1 step back ... 2 steps forward
Women with hormone-receptor positive, metastatic breast cancer may take medications for years to help keep their cancer at bay, but when the tumor becomes resistant to anti-hormonal drugs, treatment with chemotherapy becomes the only option. But a study presented today at the 2008 ASCO Breast Cancer Symposium may change this approach. Early data suggests a new treatment approach can "re-sensitize" the tumor, allowing anti-hormonal drugs to do their job once again.
How advanced prostate cancer becomes resistant to androgen-deprivation therapy
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone – the hormone that fuels prostate-cancer growth – via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.
Molecular 'clock' could predict risk for developing breast cancer
A chemical reaction in genes that control breast cancer provides a molecular clock that could one day help researchers more accurately determine a woman’s risk for developing breast cancer and provide a new approach for treatment, UT Southwestern Medical Center researchers have found.
Treatment advances for fibroids, menopause
Women with fibroids and endometriosis facing the possibility of hysterectomy may now choose less invasive treatment options to preserve fertility, according to Yale professor Aydin Arici, M.D., who will direct a scientific session exploring these alternatives at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting May 3-7 in New Orleans, Louisiana.
Osteoporosis drug fosamax linked to heart problem
Women who have used Fosamax are nearly twice as likely to develop the most common kind of chronically irregular heartbeat (atrial fibrillation) than are those who have never used it, according to research from Group Health and the University of Washington published in the April 28 Archives of Internal Medicine.
A diagnosis of triple-negative breast cancer doesn't always mean cancer spread
Triple-negative breast cancers are a heterogeneous group and may not always be associated with lymph node spread, a new study shows.
Chemotherapy-induced anemia increases risk of local breast cancer recurrence
Patients with breast cancer who developed anemia during chemotherapy had nearly three times the risk of local recurrence as those who did not, according to a study published in the April 1 issue of
Clinical Cancer Research, a journal of the American Association for Cancer Research.
New study reveals for first time how BRCA1 mutations cause breast cancer
An international team of researchers led by Columbia University Medical Center’s Herbert Irving Comprehensive Cancer Center and Sweden’s Lund University has, for the first time, revealed how mutations in the BRCA1 gene lead to breast cancer. Findings show that one way BRCA1 mutations cause cancer is by knocking out a powerful tumor suppressor gene known as PTEN.